3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF
申请人:Samumed, LLC
公开号:US20140194441A1
公开(公告)日:2014-07-10
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地,本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病(例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎),调节由Wnt途径信号介导的细胞事件,以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/疾患/疾病。还提供了治疗与Wnt相关疾病状态的方法。